Milestone as first CGRP inhibitor listed on the PBS for chronic migraine

The calcitonin gene-related peptide (CGRP) inhibitor galcanezumab (Emgality) will be PBS listed for the treatment of chronic migraine from June 1. The long-awaited PBS listing was part of the Federal Government’s Budget 2021-22 announcement which included $43 billion allocated over four years to the PBS. Neurologist Associate Professor Richard Stark, from the Alfred Hospital, welcomed ...

Already a member?

Login to keep reading.

© 2021 the limbic